Skip to main content
Erschienen in: Tumor Biology 10/2015

01.10.2015 | Research Article

FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells

verfasst von: Tian Yang, Hong Li, Asmitananda Thakur, Tianjun Chen, Jing Xue, Dan Li, Mingwei Chen

Erschienen in: Tumor Biology | Ausgabe 10/2015

Einloggen, um Zugang zu erhalten

Abstract

Family of forkhead box transcription factors, including forkhead box P4 (FOXP4), plays an important role in oncogenesis. The current study is to evaluate the role of FOXP4 in regulating human non-small cell lung cancer (NSCLC). Quantitative RT-PCR and Western blot were performed to evaluate the gene and protein expressions of FOXP4 in six NSCLC cell lines and 55 NSCLC patients. Lentivirus of small hairpin RNA (FOXP4-shRNA) was used to downregulate FOXP4 in NSCLC cell lines A549 and H1703 cells. Its effect on NSCLC growth, invasion, and cell cycle were evaluated by cell proliferation assay, migration assay, and cell cycle assay, respectively. Dual luciferase assay and Western blot were used to examine whether microRNA-138 (miR-138) was an upstream regulator of FOXP4. The dependence of FOXP4 on miR-138 associated signaling pathway was evaluated by ectopically overexpressing enhancer of zeste homolog 2 (EZH2), a known miR-138 target in NSCLC. FOXP4 was highly expressed in both NSCLC cell lines and NSCLC patients. FOXP4 downregulation by FOXP4-shRNA markedly reduced cancer cell growth and invasion, as well as induced cell cycle arrest in A549 and H1703 cells. MiR-138 was confirmed to be an upstream regulator of FOXP4 and directly regulated FOXP4 expression in A549 and H1703 cells. FOXP4 downregulation-mediated inhibition on cancer cell growth and invasion was independent on overexpressing EZH2, another direct target of miR-138 in NSCLC. Our data demonstrated that FOXP4 was a critical regulator in NSCLC and independently associated with miR-138 regulation.
Literatur
1.
Zurück zum Zitat Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561–71.CrossRef Group NM-aC. Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet. 2014;383:1561–71.CrossRef
3.
Zurück zum Zitat Barr Kumarakulasinghe N, Zanwijk NV, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology. 2015;20(3):370–8.CrossRef Barr Kumarakulasinghe N, Zanwijk NV, Soo RA. Molecular targeted therapy in the treatment of advanced stage non-small cell lung cancer (NSCLC). Respirology. 2015;20(3):370–8.CrossRef
4.
Zurück zum Zitat Umemura S, Tsuchihara K, Goto K. Genomic profiling of small-cell lung cancer: the era of targeted therapies. Jpn J Clin Oncol. 2015. [Epub ahead of print] Umemura S, Tsuchihara K, Goto K. Genomic profiling of small-cell lung cancer: the era of targeted therapies. Jpn J Clin Oncol. 2015. [Epub ahead of print]
5.
Zurück zum Zitat Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847–59.CrossRefPubMed Myatt SS, Lam EW. The emerging roles of forkhead box (Fox) proteins in cancer. Nat Rev Cancer. 2007;7:847–59.CrossRefPubMed
6.
Zurück zum Zitat Katoh M, Katoh M. Human FOX gene family (review). Int J Oncol. 2004;25:1495–500.PubMed Katoh M, Katoh M. Human FOX gene family (review). Int J Oncol. 2004;25:1495–500.PubMed
7.
Zurück zum Zitat Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 2012;138:230–5.CrossRefPubMed Feng J, Zhang X, Zhu H, Wang X, Ni S, Huang J. High expression of FoxP1 is associated with improved survival in patients with non-small cell lung cancer. Am J Clin Pathol. 2012;138:230–5.CrossRefPubMed
8.
Zurück zum Zitat Shimizu K, Kato A, Hinotsume D, Shigemura M, Hanaoka M, Shimoichi Y, et al. Reduced expressions of Foxp1 and Rassf1a genes in lung adenocarcinomas induced by N-nitrosobis (2-hydroxypropyl) amine in rats. Cancer Lett. 2006;236:186–90.CrossRefPubMed Shimizu K, Kato A, Hinotsume D, Shigemura M, Hanaoka M, Shimoichi Y, et al. Reduced expressions of Foxp1 and Rassf1a genes in lung adenocarcinomas induced by N-nitrosobis (2-hydroxypropyl) amine in rats. Cancer Lett. 2006;236:186–90.CrossRefPubMed
9.
Zurück zum Zitat Dimitrakopoulos F-ID, Papadaki H, Antonacopoulou AG, Kottorou A, Gotsis AD, Scopa C, et al. Association of FOXP3 expression with non-small cell lung cancer. Anticancer Res. 2011;31:1677–83.PubMed Dimitrakopoulos F-ID, Papadaki H, Antonacopoulou AG, Kottorou A, Gotsis AD, Scopa C, et al. Association of FOXP3 expression with non-small cell lung cancer. Anticancer Res. 2011;31:1677–83.PubMed
10.
Zurück zum Zitat Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kuwano H. Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep. 2006;15:1315–9.PubMed Ishibashi Y, Tanaka S, Tajima K, Yoshida T, Kuwano H. Expression of Foxp3 in non-small cell lung cancer patients is significantly higher in tumor tissues than in normal tissues, especially in tumors smaller than 30 mm. Oncol Rep. 2006;15:1315–9.PubMed
12.
Zurück zum Zitat Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66:7390–4.CrossRefPubMed Calin GA, Croce CM. MicroRNA-cancer connection: the beginning of a new tale. Cancer Res. 2006;66:7390–4.CrossRefPubMed
13.
14.
Zurück zum Zitat Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, et al. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem. 2013;31:56–65.CrossRefPubMed Zhang H, Zhang H, Zhao M, Lv Z, Zhang X, Qin X, et al. MiR-138 inhibits tumor growth through repression of EZH2 in non-small cell lung cancer. Cell Physiol Biochem. 2013;31:56–65.CrossRefPubMed
15.
Zurück zum Zitat Teufel A, Wong EA, Mukhopadhyay M, Malik N, Westphal H. FoxP4, a novel forkhead transcription factor. Biochim Biophys Acta. 2003;1627:147–52.CrossRefPubMed Teufel A, Wong EA, Mukhopadhyay M, Malik N, Westphal H. FoxP4, a novel forkhead transcription factor. Biochim Biophys Acta. 2003;1627:147–52.CrossRefPubMed
16.
Zurück zum Zitat Wang G, Sun Y, He Y, Ji C, Hu B, Sun Y. MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). Int J Clin Exp Pathol. 2015;8:337–44.PubMedPubMedCentral Wang G, Sun Y, He Y, Ji C, Hu B, Sun Y. MicroRNA-338-3p inhibits cell proliferation in hepatocellular carcinoma by target forkhead box P4 (FOXP4). Int J Clin Exp Pathol. 2015;8:337–44.PubMedPubMedCentral
Metadaten
Titel
FOXP4 modulates tumor growth and independently associates with miR-138 in non-small cell lung cancer cells
verfasst von
Tian Yang
Hong Li
Asmitananda Thakur
Tianjun Chen
Jing Xue
Dan Li
Mingwei Chen
Publikationsdatum
01.10.2015
Verlag
Springer Netherlands
Erschienen in
Tumor Biology / Ausgabe 10/2015
Print ISSN: 1010-4283
Elektronische ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3498-8

Weitere Artikel der Ausgabe 10/2015

Tumor Biology 10/2015 Zur Ausgabe

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Positiver FIT: Die Ursache liegt nicht immer im Dickdarm

27.05.2024 Blut im Stuhl Nachrichten

Immunchemischer Stuhltest positiv, Koloskopie negativ – in solchen Fällen kann die Blutungsquelle auch weiter proximal sitzen. Ein Forschungsteam hat nachgesehen, wie häufig und in welchen Lokalisationen das der Fall ist.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.